[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Remel Europe Ltd.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":59},{"warningLetters":4,"total":58},[5,34],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":29,"recipient_name":30,"body_fetched_at":31,"delivery_method":32,"recipient_title":20,"reference_number":20,"action_taken_date":33,"medical_device_id":20,"response_letter_date":20},2141,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2023-04-04T13:20:00Z\">04\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-17T04:00:00Z\">03\u002F17\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fold-europe-cheese-inc-644539-03172023\">Old Europe Cheese, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fold-europe-cheese-inc-644539-04052024\">\u003Ctime datetime=\"2024-04-08T04:00:00Z\">04\u002F08\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Albano Navarro\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Old Europe Cheese, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1330 E. Empire Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Benton Harbor\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>49022-2018\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nFY23- HAFE6- 02 CMS 644539\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 17, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Navarro,\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) soft and semi-soft cheese manufacturing facility, located at 1330 E. Empire Avenue, Benton Harbor, MI, from September 13, 2022 through October 6, 2022. The inspection, conducted jointly with the Michigan Department of Agriculture and Rural Development (MDARD), was initiated as part of a multistate outbreak of \u003Cem>Listeria monocytogenes\u003C\u002Fem> (\u003Cem>L. monocytogenes\u003C\u002Fem>) infections linked to RTE soft cheese products supplied by your facility. According to the Centers for Disease Control and Prevention (CDC), six (6) ill people from six (6) states were infected with the outbreak strain of \u003Cem>L. monocytogenes\u003C\u002Fem>. On September 30, 2022, your firm recalled all RTE Brie and Camembert Soft Cheese products because they had the potential of being contaminated with \u003Cem>L. monocytogenes\u003C\u002Fem>. On October 5, 2022 your firm expanded the recall to also include Baked Brie Cheeses. One (1) environmental swab isolate collected by FDA during our inspection of your manufacturing facility matched the clinical outbreak isolates, based on Whole Genome Sequencing (WGS) analysis. According to the CDC, epidemiologic, traceback, and laboratory data showed that cheese made by Old Europe Cheese, Inc. made people sick.\u003C\u002Fp>\n\n\u003Cp>During our inspection of your facility, FDA found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventative Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\u003C\u002Fp>\n\n\u003Cp>Based on our inspectional findings, we have determined that the RTE Brie and Camembert Soft Cheese products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed or held under insanitary conditions whereby they may have been contaminated with filth or rendered injurious to health. The introduction or delivery for introduction into interstate commerce of an adulterated food is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)]. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links in FDA’s home page at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing the deviations found at your facility. We received your email responses, dated October 28, 2022, November 30, 2022, January 13, 2023, and February 28, 2023. You indicated that you have voluntarily suspended operations while you conduct a root cause investigation, make facility improvements, and revise your food safety plan. Your responses to date have indicated that production will remain suspended while you implement long-term infrastructure projects and rebuild your food safety systems. We have addressed the details of your responses in this letter below. Based on our review of the inspectional findings and the responses that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Multistate Outbreak of Listeriosis Linked to Old Europe Cheese, Inc.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CDC, FDA, and State partners investigated this multistate outbreak of \u003Cem>L. monocytogenes\u003C\u002Fem> infections linked to RTE soft cheese products produced by Old Europe Cheese, Inc. This investigation included six (6) ill people in six (6) states who were infected with the outbreak strain of \u003Cem>L. monocytogenes\u003C\u002Fem>. Of six (6) patients with information available, five (5) were hospitalized. Food exposure information was collected for five (5) patients, and four (4) patients reported consumption of brie or camembert cheese. One (1) case reported purchasing Premium Cheese by Lidl brie. Old Europe Cheese, Inc. was the sole manufacturer of Premium Cheese by Lidl brie sold at stores in the U.S. Two (2) other patients also reported purchasing unknown brands of brie\u002Fcamembert; these two cases each reported shopping from a store which also received cheese products from Old Europe Cheese, Inc.\u003C\u002Fp>\n\n\u003Cp>On September 13 and 14, 2022, FDA collected samples (environmental swabs) of your production environment. FDA laboratory analysis of sample INV1084040 confirmed that (1) swab collected from a hole in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> floor was positive for \u003Cem>L. monocytogenes\u003C\u002Fem>, and we advised you of this result on September 23, 2022.\u003C\u002Fp>\n\n\u003Cp>WGS analysis was conducted of the above referenced \u003Cem>L. monocytogenes\u003C\u002Fem> isolate and it was determined that the environmental isolate matched the six (6) clinical isolates that were part of an illness outbreak cluster. We advised you of the significance of these WGS results via conference call on September 28, 2022.\u003C\u002Fp>\n\n\u003Cp>Epidemiologic, traceback, and laboratory data support a conclusion that cheese products manufactured at Old Europe Cheese, Inc. are the likely source of this outbreak of \u003Cem>L. monocytogenes\u003C\u002Fem> infections. \u003Cem>L. monocytogenes\u003C\u002Fem> is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without proper controls it can proliferate in food processing facilities where it may contaminate food.\u003C\u002Fp>\n\n\u003Cp>Therefore, it is essential to identify the areas of the food processing plant where this organism is able to grow and survive and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with \u003Cem>L. monocytogenes\u003C\u002Fem> can lead to a severe, sometimes life-threatening illness called listeriosis, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions.\u003C\u002Fp>\n\n\u003Cp>The presence of \u003Cem>L. monocytogenes\u003C\u002Fem> in your facility is significant in that it demonstrates your sanitation efforts are inadequate to effectively control pathogens in your facility to prevent contamination of food. Appropriate control of \u003Cem>L. monocytogenes\u003C\u002Fem> in a food processing environment requires knowledge of the unique characteristics of the organism and implementing the corresponding hygienic practices necessary to control this pathogen.\u003C\u002Fp>\n\n\u003Cp>We received your email responses, dated October 28, 2022, November 30, 2022, January 13, 2023, and February 28, 2023, outlining the corrective actions you have taken in response to the \u003Cem>L. monocytogenes\u003C\u002Fem> outbreak and sample findings. On September 30, 2022, your firm initiated a voluntary recall of your RTE Brie and Camembert Soft Cheese products and you expanded the recall to include Baked Brie on October 5, 2022. After the product recalls and in response to FDA’s laboratory data indicating that products manufactured at your facility were the likely source of this outbreak of \u003Cem>L. monocytogenes\u003C\u002Fem> infections, your firm voluntarily suspended production of soft cheeses. Voluntary suspension of all production in the facility (including semi-soft cheese products that are manufactured on separate equipment located in a different room than the brie cheese) occurred on October 5, 2022, to facilitate a root cause investigation within your entire facility. You began implementing corrective actions after the initial notification of the environmental sampling results on September 23, 2022, which included cleaning, sanitation, and environmental vector sampling. Thus far, you have provided results for swabs collected on September 17-18, 2022, \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples and swabs of \u003Cstrong>(b)(4)\u003C\u002Fstrong> collected on September 25, 2022, \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples. We also note that you have hired a food safety consultant and are in the process of conducting a root cause investigation, developing and\u002For updating multiple food safety procedures including environmental monitoring procedures, and making improvements to your floors, drains, walls, and ceilings. However, to date, your responses have not provided evidence that you have eliminated \u003Cem>L. monocytogenes\u003C\u002Fem> from your processing environment or effectively prevented it from contaminating finished products you may manufacture in the future.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You did not appropriately evaluate known or reasonably foreseeable hazards to determine whether they require a preventive control in your RTE soft and semi-soft cheese products (including Brie and Camembert), as required by 21 CFR 117.130(a)(1). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Your hazard analysis for soft and semi-soft cheese products determined that “Post-Pasteurization Contamination” did not require a preventive control because it was “Unlikely to occur as purity plating of production samples is performed and plant&nbsp;performance history indicates good process control.” In addition, your hazard analysis determined that “Environmental Contamination (Listeria)” did not require a preventive control because an “Environmental program is in place to test for listeria spp. Finished product testing is also performed with positive release program.” However, RTE soft and semi-soft cheese products manufactured in your facility were exposed to the environment at various post-pasteurization processing steps (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>). The packaged RTE cheese products did not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize the pathogen. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens (e.g., \u003Cem>L. monocytogenes\u003C\u002Fem>) as a hazard requiring a preventive control (i.e., sanitation controls). Sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR 117.135(c)(3)).\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analysis of the environmental samples collected on September 13 and 14, 2022 (Samples INV1084039 and INV1084040, respectively), confirmed that one (1) out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> total environmental swabs was positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. This positive swab was recovered from a hole in the floor of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Room, where the cheese products are RTE (post-pasteurization), exposed to the environment, and manually handled by employees. WGS analysis of this isolate determined it was a match to the outbreak strain.\u003C\u002Fp>\n\n\u003Cp>In addition to \u003Cem>L. monocytogenes\u003C\u002Fem>, the presence of L\u003Cem>isteria innocua\u003C\u002Fem> (\u003Cem>L. innocua\u003C\u002Fem>) was also found in your facility during the FDA environmental swabbing that occurred on September 13 and 14, 2022. \u003Cem>L. innocua\u003C\u002Fem> was detected in two (2) environmental swabs taken from the floor in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Room and a floor drain between the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Room and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hallway where the cheese products are RTE (post-pasteurization) and exposed to the environment. The presence of non-pathogenic \u003Cem>Listeria\u003C\u002Fem> species suggests that conditions are suitable for survival and\u002For growth of \u003Cem>L. monocytogenes\u003C\u002Fem> which, as noted above, has been found in your facility.\u003C\u002Fp>\n\n\u003Cp>b. Your hazard analysis for soft and semi-soft cheese products determined that “Pathogens (Salmonella, Listeria), if present” did not require a preventive control at the “Cooler Storage” step because a “Program for Cooler Temperature [sic] Control is in place. Plant does not have a history of problematic room temperatures.” However, if not properly time\u002Ftemperature-controlled, the RTE soft and semi-soft cheese products stored in your facility are likely to support the growth and toxin formation of bacterial pathogens (such as ingredient-related pathogens either surviving pasteurization or added post-pasteurization, or environmental pathogens introduced in your facility). Your RTE soft and semi-soft cheese products were not subject to formulation control in your facility to prevent such growth. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify bacterial pathogens as a hazard requiring a preventive control (i.e., process controls). Process controls include procedures, practices, and processes to ensure the control of parameters during operations such as refrigerated finished product storage. Where appropriate, process controls must also include the parameters associated with the control of the hazard and the minimum and maximum values, or combination of values, needed to significantly control the hazards (see 21 CFR 117.135(c)(1)). These controls must be validated as required by 21 CFR 117.160.\u003C\u002Fp>\n\n\u003Cp>We note that your Cooler Temperature Control program did not include written procedures including monitoring, corrective actions, or verification activities for the temperature control of your cooler, which routinely stores RTE soft cheese products including Brie and Camembert. Also, during the inspection, our investigators observed that monitoring cooler temperature only occurred \u003Cstrong>(b)(4)\u003C\u002Fstrong> on weekdays and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on weekends. Additionally, through record review during the inspection, we detected two (2) dates where temperatures were recorded as 51.2°F, 52°F and 53.1°F with no record of a corrective action documented. Soft cheeses can support the growth of pathogens, including \u003Cem>L. monocytogenes\u003C\u002Fem>, when not stored at proper refrigeration temperatures.\u003C\u002Fp>\n\n\u003Cp>c. Your hazard analysis for soft and semi-soft cheese products determined that bacterial pathogens in many ingredients added after pasteurization (e.g., peppercorns, 1\u002F8” flaked tomato, chives, basil, garlic salt, and parsley) did not require a preventive control because “Product is tested for Salmonella – COA Received per lot.” These ingredients did not undergo a kill step in your facility. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify bacterial pathogens as a hazard requiring a preventive control (i.e., supply-chain program). During our inspection, you explained that every lot of ingredients was tested for the presence of coliform colonies by laboratory personnel until June 2022, at which point the testing program was discontinued. Since that time, the certificates of analysis (COAs) for ingredients had been received by the purchasing department, and the ingredients were made immediately available for use in production.\u003C\u002Fp>\n\n\u003Cp>For those RTE products that require a preventive control for bacterial pathogens associated with the ingredients (i.e., RTE spices) and that do not undergo a kill step within your facility, you are required to establish and implement a supply-chain program in accordance with 21 CFR 117.405(a)(1). A supply-chain program includes approving suppliers and conducting appropriate supplier verification activities as described in 21 CFR 117.410. \u003Cem>Salmonella\u003C\u002Fem> in RTE spices is a hazard that can cause serious adverse health consequences or death, and thus an annual onsite audit is the appropriate supplier verification activity unless there is a written determination that other verification activities and\u002For less frequent onsite auditing of the supplier provide adequate assurance that the hazard is controlled (see 21 CFR 117.430(b)). The audit must be conducted before using the raw material or other ingredient from the supplier and at least annually thereafter (see 21 CFR 117.430(b)(1)(ii)).\u003C\u002Fp>\n\n\u003Cp>We received the revised hazard analysis provided with your October 28, 2022, response which now identifies hazards requiring a preventive control, including recontamination with environmental pathogens at your post-pasteurization steps and pathogen growth during cooler storage. Further, we note that your Raw Ingredient Hazard Analysis now includes hazards related to pathogenic bacteria (including \u003Cem>Salmonella\u003C\u002Fem>) for various ingredients, and that you are in the process of conducting supplier risk assessments and identifying a verification activity. Your response dated February 28, 2023, included your “Draft Preventive Control Temperature Monitoring Program” and associated draft procedures related to cooler temperature monitoring. Your draft monitoring procedures indicate that temperature data loggers are \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring the cooler and that there is \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your draft procedures appear to indicate that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> check corresponds to a single point in time, rather than a review of the temperatures for the entire period since the last check. Therefore, reviewing the data logger temperature data on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis does not appear adequate to ensure prompt corrective actions are taken when the temperature exceeds established maximum limits.\u003C\u002Fp>\n\n\u003Cp>2. You did not implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the RTE soft and semi-soft cheese products (including Brie and Camembert) manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act, as required by 21 CFR 117.135(a). Specifically:\u003C\u002Fp>\n\n\u003Cp>Your sanitation procedures were not fully implemented with respect to the production of soft cheeses when they are RTE (post-pasteurization). For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your sanitation procedures, as described in the document titled, “GMP Manual,” instructed employees to wash their hands “following practices that may compromise hand cleanliness.” However, on September 13, 2022, our investigators observed two (2) different employees’ hands come into contact with unclean surfaces (e.g., a hose that had been in contact with the floor); these employees \u003Cstrong>(b)(4)\u003C\u002Fstrong> their hands into a \u003Cstrong>(b)(4)\u003C\u002Fstrong> and returned directly to handling RTE brie cheese without washing their hands.\u003C\u002Fli>\n\t\u003Cli>Your Master Sanitation Schedule directed employees to clean-in-place (CIP) the brie vats with both \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution according to the production schedule. However, our investigators observed during the CIP on September 15, 2022, that the vat was only filled to approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of its volume, which resulted in the food-contact surfaces inside not being fully submerged, as would be needed to facilitate effective cleaning. One of your employees also indicated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution is not always used in the vats during the week, contrary to the instructions in the Master Sanitation Schedule.\u003C\u002Fli>\n\t\u003Cli>The objectives of your Sanitation SOP included ensuring “that all food- and non-food contact surfaces are free from soil after manufacturing\u002Fprocessing” and “will not negatively affect food quality and food safety.” However, on September 13, 2022 and September 20, 2022, food-contact cheese molds used for manufacturing RTE Brie and Camembert cheeses were observed to have food residue present after cleaning was completed.\u003C\u002Fli>\n\t\u003Cli>Post-sanitation\u002FPre-operation procedures in your Sanitation SOP required a visual inspection of processing equipment and verification of sanitation effectiveness (with \u003Cstrong>(b)(4)\u003C\u002Fstrong> swabbing) prior to use of the equipment (including food-contact surfaces). However, your Lab Preop Worksheets indicated that these activities were not performed as directed during several days in 2022. For example, neither visual inspection nor \u003Cstrong>(b)(4)\u003C\u002Fstrong> swabbing was performed on the brie vats, utensils, knives, brie \u003Cstrong>(b)(4)\u003C\u002Fstrong>, molding trays, and brie \u003Cstrong>(b)(4)\u003C\u002Fstrong> (food-contact surfaces) in five (5) out of seven (7) days of the week beginning May 29, 2022. Likewise, the same activities did not occur on five (5) out of seven (7) days of the week beginning June 5, 2022.\u003C\u002Fli>\n\t\u003Cli>Your Environmental Swabbing program required collection of a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples from designated zone 2-4 locations every \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you collected ten (10) swabs on or around May 25, 2022, and then you stated that you did not collect any more swabs until the week of this inspection, on or around September 14, 2022.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We received your status updates provided on October 28, 2022, November 30, 2022, January 13, 2023, and February 28, 2023, indicating that you have not resumed operations and are in the process of working with your consultants to evaluate the source of \u003Cem>Listeria\u003C\u002Fem> in your facility, as well as revising your cleaning and sanitation procedures, condensation control, environmental monitoring procedures, and employee training. Your responses included various draft procedures including, but not limited to, Standard Operating Procedures (SOPs) for handwashing, use of hoses, brie equipment clean-in-place (CIP), pre-operation, draft sanitation and environmental monitoring procedures as well as descriptions of ongoing facility repairs and construction.\u003C\u002Fp>\n\n\u003Cp>We will evaluate the adequacy of your corrective actions once they have been completed and additional information is provided. We will verify implementation during our next inspection of your facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>3. You did not conduct cleaning and sanitizing of utensils and equipment in a manner that protects against contamination of food, food-contact surfaces, or food-packaging materials, as required by 21 CFR 117.35(a). Specifically, on September 13, 2022 employees were observed spraying the outside of brie vats and the floor around the vats with a hose in such a manner that spray from the hose was observed contacting the floor and subsequently contacting the adjacent cheese molding machine. This machine (a food-contact surface) did not receive further cleaning or sanitization prior to being used to mold brie cheese.\u003C\u002Fp>\n\n\u003Cp>We received your responses which indicate that you conducted employee training on proper operation and storage of hoses and made changes to your Sanitation SOPs (SSOP). Your January 13, 2023, response states that your SSOPs have been updated to include employee responsibilities regarding sanitation and the frequency with which various SSOP activities are performed in product handling areas, and indicates that the general policy details the sequence of routine cleaning and sanitizing activities in production areas. Your February 28, 2023, response states that you are revising numerous sanitation procedures for the production area and the packaging area. We will evaluate the adequacy of your corrective actions once they have been completed and additional information is provided. We will verify implementation during our next inspection of your facility.\u003C\u002Fp>\n\n\u003Cp>4. Your plant is not constructed in such a manner that drip or condensate from fixtures, ducts and pipes does not contaminate food and food-contact surfaces, as required by 21 CFR 117.20(b)(4). Specifically, on September 13-20, 2022, condensation was observed throughout the facility including on areas above cheese molding equipment and RTE brie cheese. For example, condensation and dark reddish-brown stains were observed on the ceiling directly over at least ten racks of stacked food-contact cheese molds stored in the Clean Room. Clear condensation was also observed on pipes and the ceiling within two feet of exposed RTE brie cheese in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Condensation was also visible on the walls and windows near the ceiling of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Room where food-contact cheese molds were observed sitting on racks exposed to the environment in this room for approximately three hours before being moved to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Room.\u003C\u002Fp>\n\n\u003Cp>We received your responses which indicate that you have evaluated condensation in your facility, identified various improvements, and drafted sanitation and monitoring procedures and that you are in the process of implementing. We will evaluate the adequacy of your corrective actions once they have been completed and additional information is provided. We will verify implementation during our next inspection of your facility.\u003C\u002Fp>\n\n\u003Cp>The violations in this letter are not intended to be an all-inclusive list of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the Act, Include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to Lauren Sexton, Compliance Officer, 300 River Place, Suite 5900, Detroit, MI 48207. If you have any questions about this letter, please contact Lauren Sexton at (313) 393-8179 or via e-mail at Lauren.Sexton@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nDivision East 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAlbano Navarro\n\nRecipient Title\n\nGeneral Manager\n\nOld Europe Cheese, Inc.\n\n1330 E. Empire Avenue\n\nBenton Harbor, MI 49022-2018\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nFY23- HAFE6- 02 CMS 644539\n\nMarch 17, 2023\n\nDear Mr. Navarro,\n\nThe United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) soft and semi-soft cheese manufacturing facility, located at 1330 E. Empire Avenue, Benton Harbor, MI, from September 13, 2022 through October 6, 2022. The inspection, conducted jointly with the Michigan Department of Agriculture and Rural Development (MDARD), was initiated as part of a multistate outbreak of Listeria monocytogenes (L. monocytogenes) infections linked to RTE soft cheese products supplied by your facility. According to the Centers for Disease Control and Prevention (CDC), six (6) ill people from six (6) states were infected with the outbreak strain of L. monocytogenes. On September 30, 2022, your firm recalled all RTE Brie and Camembert Soft Cheese products because they had the potential of being contaminated with L. monocytogenes. On October 5, 2022 your firm expanded the recall to also include Baked Brie Cheeses. One (1) environmental swab isolate collected by FDA during our inspection of your manufacturing facility matched the clinical outbreak isolates, based on Whole Genome Sequencing (WGS) analysis. According to the CDC, epidemiologic, traceback, and laboratory data showed that cheese made by Old Europe Cheese, Inc. made people sick.\n\nDuring our inspection of your facility, FDA found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventative Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\n\nBased on our inspectional findings, we have determined that the RTE Brie and Camembert Soft Cheese products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed or held under insanitary conditions whereby they may have been contaminated with filth or rendered injurious to health. The introduction or delivery for introduction into interstate commerce of an adulterated food is prohibited under section 301(a) of the Act [21 U.S.C. § 331(a)]. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nAt the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing the deviations found at your facility. We received your email responses, dated October 28, 2022, November 30, 2022, January 13, 2023, and February 28, 2023. You indicated that you have voluntarily suspended operations while you conduct a root cause investigation, make facility improvements, and revise your food safety plan. Your responses to date have indicated that production will remain suspended while you implement long-term infrastructure projects and rebuild your food safety systems. We have addressed the details of your responses in this letter below. Based on our review of the inspectional findings and the responses that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility.\n\nMultistate Outbreak of Listeriosis Linked to Old Europe Cheese, Inc.\n\nCDC, FDA, and State partners investigated this multistate outbreak of L. monocytogenes infections linked to RTE soft cheese products produced by Old Europe Cheese, Inc. This investigation included six (6) ill people in six (6) states who were infected with the outbreak strain of L. monocytogenes. Of six (6) patients with information available, five (5) were hospitalized. Food exposure information was collected for five (5) patients, and four (4) patients reported consumption of brie or camembert cheese. One (1) case reported purchasing Premium Cheese by Lidl brie. Old Europe Cheese, Inc. was the sole manufacturer of Premium Cheese by Lidl brie sold at stores in the U.S. Two (2) other patients also reported purchasing unknown brands of brie\u002Fcamembert; these two cases each reported shopping from a store which also received cheese products from Old Europe Cheese, Inc.\n\nOn September 13 and 14, 2022, FDA collected samples (environmental swabs) of your production environment. FDA laboratory analysis of sample INV1084040 confirmed that (1) swab collected from a hole in the (b)(4) floor was positive for L. monocytogenes, and we advised you of this result on September 23, 2022.\n\nWGS analysis was conducted of the above referenced L. monocytogenes isolate and it was determined that the environmental isolate matched the six (6) clinical isolates that were part of an illness outbreak cluster. We advised you of the significance of these WGS results via conference call on September 28, 2022.\n\nEpidemiologic, traceback, and laboratory data support a conclusion that cheese products manufactured at Old Europe Cheese, Inc. are the likely source of this outbreak of L. monocytogenes infections. L. monocytogenes is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without proper controls it can proliferate in food processing facilities where it may contaminate food.\n\nTherefore, it is essential to identify the areas of the food processing plant where this organism is able to grow and survive and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with L. monocytogenes can lead to a severe, sometimes life-threatening illness called listeriosis, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions.\n\nThe presence of L. monocytogenes in your facility is significant in that it demonstrates your sanitation efforts are inadequate to effectively control pathogens in your facility to prevent contamination of food. Appropriate control of L. monocytogenes in a food processing environment requires knowledge of the unique characteristics of the organism and implementing the corresponding hygienic practices necessary to control this pathogen.\n\nWe received your email responses, dated October 28, 2022, November 30, 2022, January 13, 2023, and February 28, 2023, outlining the corrective actions you have taken in response to the L. monocytogenes outbreak and sample findings. On September 30, 2022, your firm initiated a voluntary recall of your RTE Brie and Camembert Soft Cheese products and you expanded the recall to include Baked Brie on October 5, 2022. After the product recalls and in response to FDA’s laboratory data indicating that products manufactured at your facility were the likely source of this outbreak of L. monocytogenes infections, your firm voluntarily suspended production of soft cheeses. Voluntary suspension of all production in the facility (including semi-soft cheese products that are manufactured on separate equipment located in a different room than the brie cheese) occurred on October 5, 2022, to facilitate a root cause investigation within your entire facility. You began implementing corrective actions after the initial notification of the environmental sampling results on September 23, 2022, which included cleaning, sanitation, and environmental vector sampling. Thus far, you have provided results for swabs collected on September 17-18, 2022, (b)(4) samples and swabs of (b)(4) collected on September 25, 2022, (b)(4) samples. We also note that you have hired a food safety consultant and are in the process of conducting a root cause investigation, developing and\u002For updating multiple food safety procedures including environmental monitoring procedures, and making improvements to your floors, drains, walls, and ceilings. However, to date, your responses have not provided evidence that you have eliminated L. monocytogenes from your processing environment or effectively prevented it from contaminating finished products you may manufacture in the future.\n\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\n\n1. You did not appropriately evaluate known or reasonably foreseeable hazards to determine whether they require a preventive control in your RTE soft and semi-soft cheese products (including Brie and Camembert), as required by 21 CFR 117.130(a)(1). Specifically:\n\na. Your hazard analysis for soft and semi-soft cheese products determined that “Post-Pasteurization Contamination” did not require a preventive control because it was “Unlikely to occur as purity plating of production samples is performed and plant performance history indicates good process control.” In addition, your hazard analysis determined that “Environmental Contamination (Listeria)” did not require a preventive control because an “Environmental program is in place to test for listeria spp. Finished product testing is also performed with positive release program.” However, RTE soft and semi-soft cheese products manufactured in your facility were exposed to the environment at various post-pasteurization processing steps (e.g., (b)(4)). The packaged RTE cheese products did not receive any further lethal treatment or otherwise include a control measure (such as a formulation lethal to the pathogen) that would significantly minimize the pathogen. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens (e.g., L. monocytogenes) as a hazard requiring a preventive control (i.e., sanitation controls). Sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling (see 21 CFR 117.135(c)(3)).\n\nFDA laboratory analysis of the environmental samples collected on September 13 and 14, 2022 (Samples INV1084039 and INV1084040, respectively), confirmed that one (1) out of (b)(4) total environmental swabs was positive for L. monocytogenes. This positive swab was recovered from a hole in the floor of your (b)(4) Room, where the cheese products are RTE (post-pasteurization), exposed to the environment, and manually handled by employees. WGS analysis of this isolate determined it was a match to the outbreak strain.\n\nIn addition to L. monocytogenes, the presence of Listeria innocua (L. innocua) was also found in your facility during the FDA environmental swabbing that occurred on September 13 and 14, 2022. L. innocua was detected in two (2) environmental swabs taken from the floor in the (b)(4) Room and a floor drain between the (b)(4) Room and (b)(4) Hallway where the cheese products are RTE (post-pasteurization) and exposed to the environment. The presence of non-pathogenic Listeria species suggests that conditions are suitable for survival and\u002For growth of L. monocytogenes which, as noted above, has been found in your facility.\n\nb. Your hazard analysis for soft and semi-soft cheese products determined that “Pathogens (Salmonella, Listeria), if present” did not require a preventive control at the “Cooler Storage” step because a “Program for Cooler Temperature [sic] Control is in place. Plant does not have a history of problematic room temperatures.” However, if not properly time\u002Ftemperature-controlled, the RTE soft and semi-soft cheese products stored in your facility are likely to support the growth and toxin formation of bacterial pathogens (such as ingredient-related pathogens either surviving pasteurization or added post-pasteurization, or environmental pathogens introduced in your facility). Your RTE soft and semi-soft cheese products were not subject to formulation control in your facility to prevent such growth. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify bacterial pathogens as a hazard requiring a preventive control (i.e., process controls). Process controls include procedures, practices, and processes to ensure the control of parameters during operations such as refrigerated finished product storage. Where appropriate, process controls must also include the parameters associated with the control of the hazard and the minimum and maximum values, or combination of values, needed to significantly control the hazards (see 21 CFR 117.135(c)(1)). These controls must be validated as required by 21 CFR 117.160.\n\nWe note that your Cooler Temperature Control program did not include written procedures including monitoring, corrective actions, or verification activities for the temperature control of your cooler, which routinely stores RTE soft cheese products including Brie and Camembert. Also, during the inspection, our investigators observed that monitoring cooler temperature only occurred (b)(4) on weekdays and (b)(4) on weekends. Additionally, through record review during the inspection, we detected two (2) dates where temperatures were recorded as 51.2°F, 52°F and 53.1°F with no record of a corrective action documented. Soft cheeses can support the growth of pathogens, including L. monocytogenes, when not stored at proper refrigeration temperatures.\n\nc. Your hazard analysis for soft and semi-soft cheese products determined that bacterial pathogens in many ingredients added after pasteurization (e.g., peppercorns, 1\u002F8” flaked tomato, chives, basil, garlic salt, and parsley) did not require a preventive control because “Product is tested for Salmonella – COA Received per lot.” These ingredients did not undergo a kill step in your facility. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify bacterial pathogens as a hazard requiring a preventive control (i.e., supply-chain program). During our inspection, you explained that every lot of ingredients was tested for the presence of coliform colonies by laboratory personnel until June 2022, at which point the testing program was discontinued. Since that time, the certificates of analysis (COAs) for ingredients had been received by the purchasing department, and the ingredients were made immediately available for use in production.\n\nFor those RTE products that require a preventive control for bacterial pathogens associated with the ingredients (i.e., RTE spices) and that do not undergo a kill step within your facility, you are required to establish and implement a supply-chain program in accordance with 21 CFR 117.405(a)(1). A supply-chain program includes approving suppliers and conducting appropriate supplier verification activities as described in 21 CFR 117.410. Salmonella in RTE spices is a hazard that can cause serious adverse health consequences or death, and thus an annual onsite audit is the appropriate supplier verification activity unless there is a written determination that other verification activities and\u002For less frequent onsite auditing of the supplier provide adequate assurance that the hazard is controlled (see 21 CFR 117.430(b)). The audit must be conducted before using the raw material or other ingredient from the supplier and at least annually thereafter (see 21 CFR 117.430(b)(1)(ii)).\n\nWe received the revised hazard analysis provided with your October 28, 2022, response which now identifies hazards requiring a preventive control, including recontamination with environmental pathogens at your post-pasteurization steps and pathogen growth during cooler storage. Further, we note that your Raw Ingredient Hazard Analysis now includes hazards related to pathogenic bacteria (including Salmonella) for various ingredients, and that you are in the process of conducting supplier risk assessments and identifying a verification activity. Your response dated February 28, 2023, included your “Draft Preventive Control Temperature Monitoring Program” and associated draft procedures related to cooler temperature monitoring. Your draft monitoring procedures indicate that temperature data loggers are (b)(4) monitoring the cooler and that there is (b)(4). Your draft procedures appear to indicate that the (b)(4) check corresponds to a single point in time, rather than a review of the temperatures for the entire period since the last check. Therefore, reviewing the data logger temperature data on a (b)(4) basis does not appear adequate to ensure prompt corrective actions are taken when the temperature exceeds established maximum limits.\n\n2. You did not implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the RTE soft and semi-soft cheese products (including Brie and Camembert) manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act, as required by 21 CFR 117.135(a). Specifically:\n\nYour sanitation procedures were not fully implemented with respect to the production of soft cheeses when they are RTE (post-pasteurization). For example:\n\nYour sanitation procedures, as described in the document titled, “GMP Manual,” instructed employees to wash their hands “following practices that may compromise hand cleanliness.” However, on September 13, 2022, our investigators observed two (2) different employees’ hands come into contact with unclean surfaces (e.g., a hose that had been in contact with the floor); these employees (b)(4) their hands into a (b)(4) and returned directly to handling RTE brie cheese without washing their hands.\n\nYour Master Sanitation Schedule directed employees to clean-in-place (CIP) the brie vats with both (b)(4) solution according to the production schedule. However, our investigators observed during the CIP on September 15, 2022, that the vat was only filled to approximately (b)(4) of its volume, which resulted in the food-contact surfaces inside not being fully submerged, as would be needed to facilitate effective cleaning. One of your employees also indicated that (b)(4) solution is not always used in the vats during the week, contrary to the instructions in the Master Sanitation Schedule.\n\nThe objectives of your Sanitation SOP included ensuring “that all food- and non-food contact surfaces are free from soil after manufacturing\u002Fprocessing” and “will not negatively affect food quality and food safety.” However, on September 13, 2022 and September 20, 2022, food-contact cheese molds used for manufacturing RTE Brie and Camembert cheeses were observed to have food residue present after cleaning was completed.\n\nPost-sanitation\u002FPre-operation procedures in your Sanitation SOP required a visual inspection of processing equipment and verification of sanitation effectiveness (with (b)(4) swabbing) prior to use of the equipment (including food-contact surfaces). However, your Lab Preop Worksheets indicated that these activities were not performed as directed during several days in 2022. For example, neither visual inspection nor (b)(4) swabbing was performed on the brie vats, utensils, knives, brie (b)(4), molding trays, and brie (b)(4) (food-contact surfaces) in five (5) out of seven (7) days of the week beginning May 29, 2022. Likewise, the same activities did not occur on five (5) out of seven (7) days of the week beginning June 5, 2022.\n\nYour Environmental Swabbing program required collection of a minimum of (b)(4) samples from designated zone 2-4 locations every (b)(4). However, you collected ten (10) swabs on or around May 25, 2022, and then you stated that you did not collect any more swabs until the week of this inspection, on or around September 14, 2022.\n\nWe received your status updates provided on October 28, 2022, November 30, 2022, January 13, 2023, and February 28, 2023, indicating that you have not resumed operations and are in the process of working with your consultants to evaluate the source of Listeria in your facility, as well as revising your cleaning and sanitation procedures, condensation control, environmental monitoring procedures, and employee training. Your responses included various draft procedures including, but not limited to, Standard Operating Procedures (SOPs) for handwashing, use of hoses, brie equipment clean-in-place (CIP), pre-operation, draft sanitation and environmental monitoring procedures as well as descriptions of ongoing facility repairs and construction.\n\nWe will evaluate the adequacy of your corrective actions once they have been completed and additional information is provided. We will verify implementation during our next inspection of your facility.\n\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B):\n\n3. You did not conduct cleaning and sanitizing of utensils and equipment in a manner that protects against contamination of food, food-contact surfaces, or food-packaging materials, as required by 21 CFR 117.35(a). Specifically, on September 13, 2022 employees were observed spraying the outside of brie vats and the floor around the vats with a hose in such a manner that spray from the hose was observed contacting the floor and subsequently contacting the adjacent cheese molding machine. This machine (a food-contact surface) did not receive further cleaning or sanitization prior to being used to mold brie cheese.\n\nWe received your responses which indicate that you conducted employee training on proper operation and storage of hoses and made changes to your Sanitation SOPs (SSOP). Your January 13, 2023, response states that your SSOPs have been updated to include employee responsibilities regarding sanitation and the frequency with which various SSOP activities are performed in product handling areas, and indicates that the general policy details the sequence of routine cleaning and sanitizing activities in production areas. Your February 28, 2023, response states that you are revising numerous sanitation procedures for the production area and the packaging area. We will evaluate the adequacy of your corrective actions once they have been completed and additional information is provided. We will verify implementation during our next inspection of your facility.\n\n4. Your plant is not constructed in such a manner that drip or condensate from fixtures, ducts and pipes does not contaminate food and food-contact surfaces, as required by 21 CFR 117.20(b)(4). Specifically, on September 13-20, 2022, condensation was observed throughout the facility including on areas above cheese molding equipment and RTE brie cheese. For example, condensation and dark reddish-brown stains were observed on the ceiling directly over at least ten racks of stacked food-contact cheese molds stored in the Clean Room. Clear condensation was also observed on pipes and the ceiling within two feet of exposed RTE brie cheese in (b)(4) Room (b)(4). Condensation was also visible on the walls and windows near the ceiling of the (b)(4) Room where food-contact cheese molds were observed sitting on racks exposed to the environment in this room for approximately three hours before being moved to the (b)(4) Room.\n\nWe received your responses which indicate that you have evaluated condensation in your facility, identified various improvements, and drafted sanitation and monitoring procedures and that you are in the process of implementing. We will evaluate the adequacy of your corrective actions once they have been completed and additional information is provided. We will verify implementation during our next inspection of your facility.\n\nThe violations in this letter are not intended to be an all-inclusive list of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so.\n\nIf you believe that your products are not in violation of the Act, Include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent to Lauren Sexton, Compliance Officer, 300 River Place, Suite 5900, Detroit, MI 48207. If you have any questions about this letter, please contact Lauren Sexton at (313) 393-8179 or via e-mail at Lauren.Sexton@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nDivision East 6","Old Europe Cheese, Inc.","old-europe-cheese-inc-644539-03172023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fold-europe-cheese-inc-644539-03172023","2026-10-26T08:09:37.410443+00:00","Warning Letter","Closed Out","2023-04-04","644539","Food & Beverages","2024-04-08","Division of Human and Animal Food Operations East VI","Albano Navarro","2026-08-20T01:10:18.682+00:00","VIA EMAIL WITH READ RECEIPT","2023-03-17",{"id":35,"raw":36,"subject":41,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":20,"issuing_office":40,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":20,"reference_number":56,"action_taken_date":57,"medical_device_id":20,"response_letter_date":20},1311,[37,38,39,40,41,13,13,13],"\u003Ctime datetime=\"2024-08-20T04:00:00Z\">08\u002F20\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-15T04:00:00Z\">08\u002F15\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintercos-europe-spa-682273-08152024\">Intercos Europe S.p.A\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-56\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Gianandrea Ferrari\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Intercos Europe S.p.A\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Via Guglielmo Marconi 84\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>20864\u003C\u002Fspan> \u003Cspan>Agrate Brianza\u003C\u002Fspan> \u003Cspan>MB\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Italy\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-56\u003C\u002Fp>\n\n\u003Cp>August 15, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Ferrari:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intercos Europe S.p.A, FEI 1000181428, at Via Guglielmo Marconi 84, Agrate Brianza, from March 11 to 15, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 5, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufactured over-the-counter (OTC) sunscreen drug products without adequately testing incoming raw materials including, but not limited to, glycerin for conformance with identity and other required specifications before their use in your OTC drug products. For example, you lacked an identity test to detect diethylene glycol (DEG) and ethylene glycol (EG) in all containers of all lots of glycerin before determining acceptability for use in manufacturing drug products intended for the U.S. market. The identity testing of glycerin includes a limit test per the United States Pharmacopeia (USP) to ensure it meets the relevant safety limits for the levels of DEG and EG.\u003C\u002Fp>\n\n\u003Cp>You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of their test analyses at appropriate intervals. Without adequate testing, you lack confirmation that the components conform to appropriate specifications before use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you state your raw material specifications will include all identification tests listed in the applicable monograph and you will review your related procedures. You also state you will analyze the \u003Cstrong>(b)(4)\u003C\u002Fstrong> incoming batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> for conformance to your suppliers’ specifications, and you will analyze \u003Cstrong>(b)(4)\u003C\u002Fstrong> container of high-risk components.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You lack updated procedures showing your corrective actions have been implemented. You also fail to demonstrate you have sufficiently established the reliability of your suppliers’ test results listed on their COAs. Additionally, you lack evidence showing you performed adequate testing on all containers of all lots of glycerin before its use in the manufacture of drug products. Furthermore, you did not provide a retroactive risk assessment of distributed products containing components at high-risk for DEG or EG contamination.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing reserve samples for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a reserve sample of a component lot is unavailable, perform reserve sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately investigate multiple microbial excursions of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system used to manufacture drug products. For example, the microbial results of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampled on July 26, 2023, exceeded your limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fg. You noted the result was likely due to a sampling error, but provided no assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, nor any evidence of the investigation leading to your conclusion. Additionally, despite this result, you performed no retrospective risk assessment of finished product manufactured with this \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection you stated there was no product impact because no microbial contamination was recovered from the finished product. However, microbial contamination is not uniformly distributed, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample may not be representative of the type or level of contamination that may exist in other individual units of a batch.\u003C\u002Fp>\n\n\u003Cp>Without investigations into microbial failure results in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system you cannot ensure that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> meets minimum microbiological and chemical standards suitable for the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>Our inspection also noted changes made to batch records without adequate explanation or investigation. You stated an investigation was not initiated because a supervisor made this change.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will review several procedures, including but not limited to those related to your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system and out-of-specification (OOS) investigations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You fail to provide a retrospective review of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system’s microbial results, and you lack a risk assessment of all products that may have been affected by the OOS results. Furthermore, you fail to identify the microbial species recovered from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Complete investigations into all \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results that were above your microbial action limit (whether or not later invalidated) in the previous three years from the date of this letter. The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potentially hazardous effects of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system on the quality of all drug product lots within expiry currently in the United States. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\n\t\u003Cli>A procedure governing your program for ongoing control and monitoring that ensures the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong>, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; o Adequately scoping of each investigation and its CAPA\u003Cbr>\n&nbsp; o Revised OOS investigation procedures with these and other remediations\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your laboratory records did not include complete data to support the analysis performed. For example, your finished product test method for zinc oxide concentration requires the recording of solvent amounts used in sample preparation. However, solvent information, including lot numbers and quantities, was not documented. In addition, your procedure requires laboratory equipment to be operated at predetermined conditions, but it does not require peer review to verify these conditions and the data generated from your testing process.\u003C\u002Fp>\n\n\u003Cp>Reliability of data is compromised when there is a failure to maintain complete records of the conditions and data associated with all tests. Furthermore, the lack of complete data compromises the quality unit’s (QU) ability to investigate discrepancies and exercise its function of ensuring compliance to applicable standards.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will create a detailed checklist describing reagent preparation. You also state your COA and laboratory notebook will be signed by the analytical quality control manager before batch release.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You fail to provide a comprehensive evaluation of your overall testing and documentation practices to assess the scope of your laboratory documentation deficiencies.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A comprehensive independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\n\t\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Intercos Europe S.p.A, Agrate Brianza into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000181428 and ATTN: Matthew Jensen.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-24-56\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Gianandrea Ferrari\n\nRecipient Title\n\nCEO\n\nIntercos Europe S.p.A\n\nVia Guglielmo Marconi 84\n\n20864 Agrate Brianza MB\n\nItaly\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-56\n\nAugust 15, 2024\n\nDear Mr. Ferrari:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Intercos Europe S.p.A, FEI 1000181428, at Via Guglielmo Marconi 84, Agrate Brianza, from March 11 to 15, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 5, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou manufactured over-the-counter (OTC) sunscreen drug products without adequately testing incoming raw materials including, but not limited to, glycerin for conformance with identity and other required specifications before their use in your OTC drug products. For example, you lacked an identity test to detect diethylene glycol (DEG) and ethylene glycol (EG) in all containers of all lots of glycerin before determining acceptability for use in manufacturing drug products intended for the U.S. market. The identity testing of glycerin includes a limit test per the United States Pharmacopeia (USP) to ensure it meets the relevant safety limits for the levels of DEG and EG.\n\nYou also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of their test analyses at appropriate intervals. Without adequate testing, you lack confirmation that the components conform to appropriate specifications before use in the manufacture of your drug products.\n\nIn your response, you state your raw material specifications will include all identification tests listed in the applicable monograph and you will review your related procedures. You also state you will analyze the (b)(4) incoming batch (b)(4) for conformance to your suppliers’ specifications, and you will analyze (b)(4) container of high-risk components.\n\nYour response is inadequate. You lack updated procedures showing your corrective actions have been implemented. You also fail to demonstrate you have sufficiently established the reliability of your suppliers’ test results listed on their COAs. Additionally, you lack evidence showing you performed adequate testing on all containers of all lots of glycerin before its use in the manufacture of drug products. Furthermore, you did not provide a retroactive risk assessment of distributed products containing components at high-risk for DEG or EG contamination.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing reserve samples for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a reserve sample of a component lot is unavailable, perform reserve sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to adequately investigate multiple microbial excursions of your (b)(4) system used to manufacture drug products. For example, the microbial results of (b)(4) sampled on July 26, 2023, exceeded your limit of (b)(4) cfu\u002Fg. You noted the result was likely due to a sampling error, but provided no assessment of your (b)(4) system, nor any evidence of the investigation leading to your conclusion. Additionally, despite this result, you performed no retrospective risk assessment of finished product manufactured with this (b)(4). During the inspection you stated there was no product impact because no microbial contamination was recovered from the finished product. However, microbial contamination is not uniformly distributed, and (b)(4) sample may not be representative of the type or level of contamination that may exist in other individual units of a batch.\n\nWithout investigations into microbial failure results in your (b)(4) system you cannot ensure that your (b)(4) meets minimum microbiological and chemical standards suitable for the manufacture of your drug products.\n\nOur inspection also noted changes made to batch records without adequate explanation or investigation. You stated an investigation was not initiated because a supervisor made this change.\n\nIn your response, you state you will review several procedures, including but not limited to those related to your (b)(4) system and out-of-specification (OOS) investigations.\n\nYour response is inadequate. You fail to provide a retrospective review of your (b)(4) system’s microbial results, and you lack a risk assessment of all products that may have been affected by the OOS results. Furthermore, you fail to identify the microbial species recovered from your (b)(4) samples.\n\nIn response to this letter, provide:\n\nComplete investigations into all (b)(4) test results that were above your microbial action limit (whether or not later invalidated) in the previous three years from the date of this letter. The investigations should detail your findings regarding the root causes of the contamination.\n\nA detailed risk assessment addressing the potentially hazardous effects of your (b)(4) system on the quality of all drug product lots within expiry currently in the United States. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nA comprehensive, independent assessment of the design and control of your firm’s (b)(4) system, with a detailed and thorough review of all microbiological hazards.\n\nA procedure governing your program for ongoing control and monitoring that ensures the (b)(4) system consistently produces (b)(4) that meets (b)(4), USP monograph specifications and appropriate microbial limits.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations\n\n3. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).\n\nYour laboratory records did not include complete data to support the analysis performed. For example, your finished product test method for zinc oxide concentration requires the recording of solvent amounts used in sample preparation. However, solvent information, including lot numbers and quantities, was not documented. In addition, your procedure requires laboratory equipment to be operated at predetermined conditions, but it does not require peer review to verify these conditions and the data generated from your testing process.\n\nReliability of data is compromised when there is a failure to maintain complete records of the conditions and data associated with all tests. Furthermore, the lack of complete data compromises the quality unit’s (QU) ability to investigate discrepancies and exercise its function of ensuring compliance to applicable standards.\n\nIn your response, you state you will create a detailed checklist describing reagent preparation. You also state your COA and laboratory notebook will be signed by the analytical quality control manager before batch release.\n\nYour response is inadequate. You fail to provide a comprehensive evaluation of your overall testing and documentation practices to assess the scope of your laboratory documentation deficiencies.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA comprehensive independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Intercos Europe S.p.A, Agrate Brianza into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000181428 and ATTN: Matthew Jensen.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Intercos Europe S.p.A","intercos-europe-spa-682273-08152024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fintercos-europe-spa-682273-08152024","2026-10-26T08:08:59.78683+00:00","Issued","2024-08-20","682273","Drugs","Mr. Gianandrea Ferrari","2026-08-19T23:52:59.104+00:00","VIA Electronic Mail","320-24-56","2024-08-15",2,{"510k":60,"classification":61,"enforcement":62,"event":63,"event_backfill":64,"pma":65,"warning_letter":66},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]